LIVAZO

This brand name is authorized in Germany, Ireland, Poland, Spain.

Active ingredients

The drug LIVAZO contains one active pharmaceutical ingredient (API):

1	Pitavastatin UNII IYD54XEG3W - PITAVASTATIN CALCIUM
	Pitavastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the biosynthesis of cholesterol, and inhibits cholesterol synthesis in the liver.
	Read more about Pitavastatin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LIVAZO Film-coated tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C10AA08	Pitavastatin	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AA HMG CoA reductase inhibitors
Discover more medicines within C10AA08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	11613906, 11613912, 11613929
ES	Centro de información online de medicamentos de la AEMPS	5324538, 5324538IP, 5324553, 73037, 73038, 73039
PL	Rejestru Produktów Leczniczych	100249908, 100249914, 100249920